

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/564	A1	(11) International Publication Number: WO 97/06440 (43) International Publication Date: 20 February 1997 (20.02.97)
(21) International Application Number: PCT/KR96/00132 (22) International Filing Date: 6 August 1996 (06.08.96) (30) Priority Data: 1995/24341 7 August 1995 (07.08.95) KR (71)(72) Applicant and Inventor: KIM, Think, You [KR/KR]; 7-1207, Hanyang Apartment, Jayang-dong, Kwangjin-ku, Seoul 143-190 (KR). (74) Agents: YOON, Dong, Yol et al.; Yoon & Lee International Patent & Law Firm, 648-23, Yoksam-dong, Kangnam-ku, Seoul 135-081 (KR).	(81) Designated States: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	

(54) Title: METHOD FOR DIAGNOSING AUTOIMMUNE DISEASES**(57) Abstract**

Disclosed herein is a method for diagnosing autoimmune diseases. It comprises a step of immunologically detecting autoantibodies in body fluids of a subject suspected to have an autoimmune disease, said autoantibodies ("anti-MTOC-MT antibodies") being against microtubule organizing center ("MTOC"), microtubules ("MT") extending from the MTOC or accompanying proteins. It provides a simple, highly specific and highly reliable diagnosis of autoimmune disease including rheumatoid arthritis.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

METHOD FOR DIAGNOSING AUTOIMMUNE DISEASES

BACKGROUND OF THE INVENTION

1. FIELD OF THE INVENTION

The present invention is related to a novel
5 diagnostic method of autoimmune diseases. More
specifically, the present invention is related to a
novel method of diagnosing autoimmune diseases by
immunologically detecting antibodies to microtubule
organizing center (hereinafter, referred to as
10 "MTOC") and/or microtubules extending therefrom
and/or accompanying proteins present in human and
animal tissues or cells.

2. DESCRIPTION OF THE PRIOR ARTS

An autoimmune disease, an immune system
15 disorder causing formation of antibodies against
endogenous materials and not against foreign
materials, may be classified into two categories:
systemic rheumatic diseases and organ-specific
autoimmune diseases. The systemic rheumatic
20 diseases again may be classified into many kinds of
diseases including systemic lupus erythematosus,
rheumatoid arthritis, or the like.

Rheumatoid arthritis is a very frequently
occurring disease, which is found in 1 - 5% of the
25 world's populations. Its typical symptoms include
morning stiffness and joint pains of the hands and

feet.

Since the etiology of rheumatoid arthritis is still unknown, its successful therapy or accurate diagnosis is not easy.

5 Until now, the rheumatoid factor has been detected to diagnose rheumatoid arthritis. However, the rheumatoid factor is not detected in all patients with the disease, and furthermore, shows positive results in about 5 - 20% of normal
10 persons. (ARA Glossary Committee, Dictionary of the rheumatic disease 11, diagnostic testing, p. 17, 1985)

15 To avoid these problems, anti-keratin, anti-perinuclear factor and anti-RA-33 antibodies were developed. These antibodies contributed in improving the diagnostic specificity of rheumatoid arthritis. However, the sensitivity is still low to use in practice.

20 In particular, the ANA test ("Anti-nuclear antibody test") has been the most widely used test in diagnosing autoimmune diseases. However, the conventional ANA test employing the HEp-2 cell line is mainly directed to detect systemic lupus erythematosus. Therefore, it is necessary to
25 detect the rheumatoid factor separately in order to diagnose rheumatoid arthritis.

The present inventor had found that a macrophage is more useful than the conventionally used HEp-2 cell to diagnose autoimmune diseases, and

succeeded in establishing a macrophage cell line.

The established cell line was named "IT-1" and was deposited at the Korean Culture Collection of Microorganisms, Yonsei University located in Seoul, Korea, under Accession No. KFCC 10772 according to the Budapest Treaty.

As a result of continuing extensive research, the present inventor surprisingly found that body fluids of patients with rheumatoid arthritis characteristically contain antibodies against microtubule organizing center ("MTOC") and/or microtubules ("MT") extending therefrom.

SUMMARY OF THE INVENTION

Thus, an object of the present invention is to provide a method for diagnosing autoimmune diseases with high specificity and sensitivity.

Another object of the present invention is to provide a method for diagnosing autoimmune diseases comprising steps of:

contacting a body fluid sample of a subject suspected to have an autoimmune disease with any living tissue or cell line; and

determining whether or not MTOC and/or MT and/or accompanying proteins have reacted with anti-MTOC-MT antibodies in the body fluid.

The present invention also provides a method

for detecting anti-nuclear antibody, anti-cytoplasmic antibody and anti-MTOC-MT antibodies simultaneously by using a tissue or cell.

5 The present invention further provides a method for diagnosing autoimmune diseases comprising the following steps:

preparing a glass slide, on which a tissue or cell is immobilized;

10 preparing a body fluid sample of a subject suspected to have an autoimmune disease;

contacting the body fluid sample with the tissue or cell on the glass slide and incubating at a certain temperature for a certain period of time; and

15 detecting the presence of anti-MTOC-MT antibodies, which respond to the MTOC, MT or accompanying proteins in the tissue or cell.

BRIEF DESCRIPTION OF DRAWINGS

20 This invention will be described in more detail with reference with accompanying drawings in which:

FIG. 1 is a fluorescent microscopic picture showing anti-MTOC-MT antibodies detected by an indirect immunofluorescence technique using the IT-1 cell. The MTOC is located near the nucleus of the
25 IT-1 cell, and thread-like MT extending from the MTOC can be seen.

The above and other objects, features and applications of the present invention will be apparent to those skilled in the art from the following detailed explanation.

5

DETAILED EXPLANATION OF THE INVENTION

The present invention is based on the inventor's surprising findings that the body fluids of patients with rheumatoid arthritis characteristically contain autoantibodies against microtubule organizing center ("MTOC"), and/or microtubules ("MT") extending therefrom, and/or proteins accompanying MTOC and MT. The MTOC, MT and accompanying proteins occur in all of the tissues or cells originating from animals including human beings. Moreover, it is strongly expected that the MTOC, MT and accompanying proteins occur in insects.

The term "anti-MTOC-MT antibodies" employed throughout the application means and includes all antibodies to MTOC, MT, proteins accompanying MTOC and proteins accompanying MT. This is based on the fact that autoantibodies in the body fluid of patients with autoimmune diseases can immunologically respond to one, two or all of the MTOC, MT and accompanying proteins. Herein, the antibodies are autoantibodies and present in

patients with autoimmune diseases, particularly body fluids of patients with rheumatoid arthritis.

For the present invention, the origin and kind of tissues or cells that serve as a source of MTOC, MT and accompanying proteins which react with anti-MTOC-MT antibodies of patients with autoimmune diseases is not particularly limited. The MTOC, MT and accompanying proteins occur in all tissues or cells of humans, animals such as rats, mice, rabbits, cows, and insects. As for the kind of the tissues or cells, for the purpose of simple and easy use, any established tissue or cell may be advantageously used. For example, the IT-1 cell line (KFCC 10772), an established macrophage cell line provided by the present inventor may advantageously be used. Or a human cancer cell such as HEp-2 (deposited at ATCC under accession number CCL 23 or commercially available) can be advantageously employed. In particular, the IT-1 cell line can be more advantageously used, since it renders a more accurate and clearer detection of the MTOC and MT of patients with autoimmune diseases.

Moreover, for more convenient applications, the tissues or cells can be immobilized onto a glass slide. Immobilization of human tissues or cells on the glass slide can be carried out by using conventional methods. The parameters such as time, temperature and fixatives may be chosen without difficulty by those skilled in the technique and do

not limit the present invention. As fixatives, organic solvents such as ethanol, acetone, or methanol, and cross-linking reagents such as paraformaldehyde or glutaraldehyde, in single or as mixtures thereof may advantageously be employed.

When the tissues or cells are immobilized on the glass slide, the tissues or cells may be treated to remove their cell wall in order to attain an easy and clear reading of the results. For this purpose, surface active agents such as Triton-XTM may be employed.

The results of immunological reactions between MTOC, MT and/or accompanying proteins in tissues or cells and anti-MTOC-MT antibodies in patients can be detected by using any conventional technique employed for detecting immunological reactions. Indirect immunofluorescence technique, immunoenzyme technique and radioimmunoassay, for example, can be used.

Until now, as described above, two or more separate tests, e.g., ANA (Anti-Nuclear Antibody) test plus rheumatoid factor had to be carried out to obtain a reliable result for autoimmune disease diagnosis. In contrast, the present invention allows use of established cell lines such as human macrophage IT-1 or human cancer cell HEp-2 to be used as human tissues or cells to detect not only anti-MTOC-MT antibodies but also anti-nuclear antibodies simultaneously, thereby making it

possible to detect a more broad spectrum of autoimmune diseases including rheumatoid arthritis.

5 The body fluid of patients with autoimmune diseases may include, but not limited thereto, blood samples such as whole blood, serum, or plasma, synovial fluids, cerebrospinal fluids, or pleural fluids.

10 The method for diagnosing rheumatoid arthritis using tissues or cell lines will be described in more detail hereinafter.

15 A glass slide having a tissue or cell line immobilized thereon is prepared. A series of two-fold dilutions (each 30 microliters) (from 1:20 to 1:1280 dilutions) of body fluid from a patient with rheumatoid arthritis are dropped onto the glass slide. After allowing to react at room temperature and high humidity for about 30 minutes, the glass slide is placed into a Copran jar containing phosphate buffered saline (PBS), agitated at 200 rpm using an agitator, washed and dried. Thirty microliters of a dilution (1:40) of fluorescein-conjugated polyvalent anti-human immunoglobulin (Dako) is dropped on the slide, which is then allowed to react at room temperature and high humidity for about 30 minutes. After washing the slide with PBS, the slide is counter-stained by using 0.2% Evans' blue (Sigma) and washed with PBS.

25 The excessive buffer is removed using an absorptive paper, a PBS-glycerol solution is mounted

thereon, and observed under a fluorescent microscope.

Circular or ring-shaped fluorescent patterns of the MTOC are observed near the nucleus. The thread-like MTs extending from the MTOC are also observed (FIG. 1). Such patterns are morphological characteristics of the MTOC and MT, respectively (Molecular Biology of the Cell, 3rd Ed., Garland, pp 789-795).

Antibodies detected in the body fluid of patients with autoimmune disease, particularly, rheumatoid arthritis are presumed to be antibodies against MTOC, MT and accompanying proteins. The present inventor named the fluorescent pattern in FIG. 1 as "perinuclear single large granular with skeleton", which is a characteristic of rheumatoid arthritis.

PREFERRED EMBODIMENTS OF THE INVENTION

The present invention will be embodied by way of the following examples. However, these examples are provided for the illustration purpose only and should not be construed as limiting the scope of the invention, which is properly delineated in the accompanying claims. The parts or percents in the Examples are based on the weight, unless indicated otherwise.

Example 1

2 X 10⁴ cells/ml of IT-1 cell line (KFCC 10772) cultured in RPMI-1640 supplemented with 10% bovine serum were placed into wells of glass slides. The cells were grown in an incubator under 5% CO₂ atmosphere at 37°C for 24 hours. The culture media was removed from the slides, and the slides were washed with PBS and immersed into an acetone-methanol mixture (1:1) for 5 minutes for fixation.

Serum samples from 269 patients with rheumatoid arthritis, which were stored at -70°C, were successively diluted two-fold from 1:20 to 1:1280.

Thirty microliters of each dilution was dropped on the slides and allowed to react at room temperature and high humidity for 30 minutes.

The glass slides were then placed into a Copran jar containing PBS, and agitated at 200 rpm using an agitator, washed and dried. Thirty microliters of a dilution (1:40) of fluorescein-conjugated polyvalent anti-human immunoglobulin (Dako) was dropped on the slides, which were then allowed to react at room temperature and high humidity for about 30 minutes. After washing the slides with PBS, the slides were counter-stained by using 0.2% Evans' blue (Sigma) and washed with PBS. The excessive PBS was removed using an absorptive paper, a PBS-glycerol solution was mounted thereon, and observed under a fluorescent microscope.

The result is shown in FIG. 1. Circular or

ring-shaped fluorescent patterns of the MTOC were observed near the nucleus. The thread-like MT extending from the MTOC, were also observed. That is to say, the pattern of "perinuclear single large granular with skeleton" was observed.

Comparative Example 1

Diagnosis of rheumatoid arthritis through rheumatoid factor test

0.05 ml of serum samples, which were the same as those used in Example 1, were dropped onto a glass slide, and the same amount of human gamma globulin emulsion (Iatron) was added thereto. The mixture was mixed well and allowed to stand for 1 minute. Then, the glass slide was gently shaken in a horizontal direction and any aggregation was observed.

Results

148 (55%) among 269 samples showed positive reactions in the inventive test (Example 1) and rheumatoid factor test (Comparative Example 1). 62 (23%) samples were negative in rheumatoid factor test and positive in the inventive test, while 42 (16%) samples were negative in rheumatoid factor test and positive in the inventive test. And, 17 samples (6%) were negative in both tests.

These results indicate that the inventive method is highly sensitive compared with the conventional rheumatoid factor test, thereby

12

significantly reducing the probability of false negative results.

Example 2

5 The procedures in Example 1 and Comparative Example 1 were carried out using blood samples of 125 normal human beings.

10 At 1:20 dilution, the inventive test gave 4% (5 among 125) positive results, while the rheumatoid factor test gave 9.6% (12 among 125) positive results. Accordingly, it can be proven that the inventive method using anti-MTOC-MT antibodies reduces the probability of false positive results. Therefore, the inventive method can increase
15 specificity.

Example 3

 Blood samples of twelve patients showing positive results in both of the inventive and rheumatoid factor tests were prepared. The
20 procedure of Example 1 was carried out using the same blood samples on commercially available HEp-2 cells purchased from Kallestad (USA) or MBL (Japan) instead of the IT-1 cells.

 Both experiments gave positive anti-MTOC-MT
25 antibody results. However, HEp-2 cells from the two companies showed weaker fluorescence than the IT-1 cell line of Example 1. Moreover, tests using HEp-2 cells showed only very small-sized anti-

MTOC antibodies.

Example 4

5 The procedure of Example 1 was carried out with the exception that the IT-1 cell line was fixed with a mixture of 4% paraformaldehyde/0.2% Triton-X, or treated with 0.5% Triton-X, respectively. The results showed more clear fluorescent patterns when treated with 0.5% Triton-X.

10 Example 5

Patients with rheumatoid arthritis usually experience articular edema and an increase of synovial fluid. So, synovial fluid may be used to detect anti-MTOC-MT antibodies.

15 The procedure of Example 1 was carried out with the exception that synovial fluid from ten patients with rheumatoid arthritis was used. As a result, all synovial samples showed positive results.

Example 6

20 The procedure of Example 1 was carried out with the exception that McCoy cells (ATCC CRL 1696) and a macrophage cell line of mouse origin (RAW cell, ATCC TIB 71) were used instead of the IT-1 cells.

25 These cells were used to make the glass slides on which sera from twelve patients known to be anti-MTOC-MT positive were applied. These mouse cell lines showed the anti-MTOCs to be much smaller

14

compared to those seen with the IT-1 cells, but the anti-MT showed positive results.

CLAIMS

1. A method for diagnosing an autoimmune disease comprising a step of immunologically detecting autoantibodies in body fluids of a subject suspected to have an autoimmune disease, said autoantibodies ("anti MTOC-MT antibodies") being against microtubule organizing center ("MTOC"), microtubules ("MT") extending from the MTOC or accompanying proteins.

2. The method of claim 1, wherein said autoimmune disease is rheumatoid arthritis.

3. The method of claim 1, wherein the step of immunologically detecting autoantibodies is carried out by contacting the body fluids with tissues or cells.

4. The method of claim 3, wherein said tissues or cells are originated from humans, animals, or insects.

5. The method of claim 4, wherein said tissues or cells are cultivated or established.

6. The method of claim 5, wherein said cells are HEp-2, macrophages, macrophage cell lines or McCoy cells.

7. The method of claim 6, wherein said macrophage cell line is IT-1 cell line (KFCC 10772).

5 8. The method of any one of claims 4 to 7, wherein the human tissues or cells are adhered to a glass slide, or cultivated and then immobilized on a glass slide.

10 9. The method of claim 8, wherein said adherence or fixation is carried out by using organic solvents or cross-linking reagents.

10. The method of any one of claims 4 to 7, wherein the tissues or cells are treated with a surface active agent.

15 11. The method of claim 1, wherein the immunological detection is carried out by indirect immunofluorescence technique.

20 12. The method of any one of claims 3 to 7, which comprises a detection of anti-MTOC-MT antibodies as well as anti-nuclear and anti-cytoplasmic antibodies.

13. The method of claim 11, wherein indirect immunofluorescence technique gives a fluorescent pattern of perinuclear single large granular with

skeleton.

14. The method of claim 1, wherein the body fluids are blood or synovial fluid.

1/1

FIG. 1



INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 96/00132

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶: G 01 N 33/564

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶: G 01 N 33/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS, WPIL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Chemical Abstracts, Vol.118, No.19, 10 May 1993 (Columbus, Ohio, USA), page 657, column 2, abstract No. 188647y, RATTNER, J.B. et al.: "MSA-35: A protein identified by human autoantibodies that colocalizes with microtubules", & Biochem. Cell Biol. 1992, 70(10-11), 1115-22.	1-14
A	Chemical Abstracts, Vol.105, No.21, 24 November 1986 (Columbus, Ohio, USA), page 551, columns 1,2, abstract No.188991n, GRUBAUER, G. et al.: "Apoptotic keratin bodies as autoantigen causing the production of IgM-anti-keratin intermediate filament autoantibodies", & J.Invest.Dermatol. 1986, 87(4), 466-71.	1-14
A	Chemical Abstracts, Vol.112, No.13, 26 March 1990 (Columbus, Ohio, USA), page 296, columns 1,2, abstract No.114226q, SAMESHIMA, M.: "Cell polarity and the MTOC", & Saibo 1989, 21(10), 389-93.	1-14

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

24 October 1996 (24.10.96)

Date of mailing of the international search report

04 November 1996 (04.11.96)

Name and mailing address of the ISA/ AT
AUSTRIAN PATENT OFFICE
Kohlmarkt 8-10
A-1014 Vienna
Facsimile No. 1/53424/535

Authorized officer

Schnass

Telephone No. 1/5337058/35

Form PCT/ISA/210 (second sheet) (July 1992)

THIS PAGE BLANK (USPTO)